ADRA2B

Across TCGA pan-cancer cohorts, ADRA2B RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ADRA2B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where ADRA2B RNA is repressed in tumor relative to normal tissue. In most cancer types ADRA2B is over-expressed in tumor, although a few such as KIRP and LIHC show the opposite, repressed pattern.

KIRP, LIHC, and BRCA are the cancer types where ADRA2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADRA2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Male	II,III,IV	−1.776	<.001	11	view →
LIHC	Female	All	−0.996	<.001	8	view →
BRCA	All	II,III,IV	−0.862	<.001	6	view →
LUSC	All	All	+1.097	<.001	5	view →
THCA	All	II,III,IV	−0.313	.003	5	view →
KIRC	Female	All	+0.641	.001	3	view →
UCEC	All	IV	+1.605	<.001	2	view →
BLCA	Male	All	−1.172	.020	2	view →
PRAD	All	All	−0.679	<.001	2	view →
CHOL	All	All	−0.976	.008	1	view →
ESCA	Male	All	+0.736	.021	1	view →
HNSC	Female	IV	−0.426	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ADRA2B–KIRP

Open the KIRP breakdown →